Header Logo

KENNETH R HESS

TitleProfessor
InstitutionMD Anderson
DepartmentBiostatistics
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032. PMID: 37114244; PMCID: PMC10129387.
      Citations:    
    2. Liedtke C, Mazouni C, Hess KR, Andr? F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. J Clin Oncol. 2023 04 01; 41(10):1809-1815. PMID: 36989609.
      Citations:    Fields:    
    3. Yennurajalingam S, Valero V, Lu Z, Liu DD, Busaidy NL, Reuben JM, Diaz Fleming C, Williams JL, Hess KR, Basen-Engquist K, Bruera E. Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial. J Natl Compr Canc Netw. 2021 12 29; 20(3):235-243. PMID: 34965510.
      Citations:    Fields:    
    4. Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado M, Garcia MM. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab079. PMID: 34377987; PMCID: PMC8350154.
      Citations: 1     
    5. Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Valero V, Lucci A, Le-Petross HC, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers (Basel). 2020 Oct 24; 12(11). PMID: 33114311; PMCID: PMC7690918.
      Citations:    
    6. Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GM. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12. PMID: 32920733; PMCID: PMC8294182.
      Citations: 2     Fields:    Translation:Humans
    7. Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol. 2020 12; 15(12):1919-1927. PMID: 32916308; PMCID: PMC10600713.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    8. Bashour SI, Ibrahim NK, Schomer DF, Hess KR, Gao C, Tripathy D, Fuller GN. Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype. Br J Cancer. 2020 10; 123(9):1417-1423. PMID: 32747747; PMCID: PMC7591856.
      Citations: 1     Fields:    Translation:Humans
    9. Iwase T, Harano K, Masuda H, Kida K, Hess KR, Wang Y, Dirix L, Van Laere SJ, Lucci A, Krishnamurthy S, Woodward WA, Layman RM, Ueno NT, Bertucci F. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. 2020 May 18; 20(1):430. PMID: 32423453; PMCID: PMC7236459.
      Citations: 2     Fields:    Translation:Humans
    10. Tapia C, Aung PP, Roy-Chowdhuri S, Xu M, Ouyang F, Alshawa A, Hajjar J, Singh G, Yang V, Castillo L, Le H, Murthy R, Stephen B, Hess KR, Wistuba I, Naing A. Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1). PMID: 32303619; PMCID: PMC7204618.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    11. Murthy RK, Song J, Raghavendra AS, Li Y, Hsu L, Hess KR, Barcenas CH, Valero V, Tripathy D, Hortobagyi GN, Carlson RW. Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. NPJ Breast Cancer. 2020; 6:11. PMID: 32219153; PMCID: PMC7096449.
      Citations: 1     
    12. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1). PMID: 32188704; PMCID: PMC7078933.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    13. Yalniz C, Campbell D, Le-Petross C, Shin K, Bevers TB, Hess KR, Whitman GJ. The role of magnetic resonance imaging in patients with palpable breast abnormalities and negative mammographic and sonographic findings. Breast J. 2020 07; 26(7):1289-1295. PMID: 32108973.
      Citations:    Fields:    Translation:Humans
    14. Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res. 2020; 10(2):648-661. PMID: 32195033; PMCID: PMC7061756.
      Citations: 17     
    15. Grant SR, Lei X, Hess KR, Smith GL, Matin SF, Wood CG, Nguyen Q, Frank SJ, Anscher MS, Smith BD, Karam JA, Tang C. Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation. Adv Radiat Oncol. 2020 May-Jun; 5(3):495-502. PMID: 32529146; PMCID: PMC7276675.
      Citations: 2     
    16. Yennurajalingam S, Carmack C, Balachandran D, Eng C, Lim B, Delgado M, Guzman Gutierrez D, Raznahan M, Park M, Hess KR, Williams JL, Lu Z, Ochoa J, Bruera E. Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. BMJ Support Palliat Care. 2021 Jun; 11(2):170-179. PMID: 31924662.
      Citations: 1     Fields:    Translation:Humans
    17. Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504. PMID: 31932214; PMCID: PMC7160008.
      Citations: 7     Fields:    Translation:Humans
    18. Karbasian N, Sohrabi S, Omofoye TS, Le-Petross H, Arun BK, Albarracin CT, Hess KR, Gutierrez-Barrera AM, Whitman GJ. Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. Curr Probl Diagn Radiol. 2021 May-Jun; 50(3):303-307. PMID: 32033821; PMCID: PMC7340565.
      Citations:    Fields:    Translation:Humans
    19. Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931. PMID: 31852833; PMCID: PMC7771658.
      Citations: 17     Fields:    Translation:Humans
    20. Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604. PMID: 31529018; PMCID: PMC6749545.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    21. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909. PMID: 31658994; PMCID: PMC6891218.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    22. Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2020 02; 15(2):266-273. PMID: 31605794.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    23. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394. PMID: 31461380; PMCID: PMC7351336.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    24. Ruiz-Flores L, Whitman GJ, Le-Petross HTC, Hess KR, Parikh JR. Variation in Technical Quality of Breast MRI. Acad Radiol. 2020 04; 27(4):468-475. PMID: 31371208.
      Citations: 1     Fields:    Translation:Humans
    25. Martaindale S, Omofoye TS, Teichgraeber DC, Hess KR, Whitman GJ. Imaging Follow-up Versus Surgical Excision for Radial Scars Identified on Tomosynthesis-Guided Core Needle Biopsy. Acad Radiol. 2020 03; 27(3):389-394. PMID: 31311772.
      Citations: 2     Fields:    Translation:Humans
    26. Vedantam A, Bruera E, Hess KR, Dougherty PM, Viswanathan A. Somatotopy and Organization of Spinothalamic Tracts in the Human Cervical Spinal Cord. Neurosurgery. 2019 06 01; 84(6):E311-E317. PMID: 30011044; PMCID: PMC6702412.
      Citations:    Fields:    Translation:Humans
    27. Asare EA, Silva-Figueroa A, Hess KR, Busaidy N, Graham PH, Grubbs EG, Lee JE, Williams MD, Perrier ND. Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center. Ann Surg Oncol. 2019 Oct; 26(11):3593-3599. PMID: 31111352.
      Citations: 7     Fields:    Translation:Humans
    28. Eghtedari M, Le-Petross H, Babiera GV, Albarracin CT, Hess KR, Woodtichartpreecha P, Whitman GJ. Not all patients with a diagnosis of a radial scar require excision. Breast J. 2019 07; 25(4):792-794. PMID: 31087426.
      Citations: 1     Fields:    Translation:Humans
    29. Teichgraeber DC, Martaindale S, Omofoye TS, Hess KR, Parikh JR, Whitman GJ. Immediate Migration of Biopsy Clip Markers After Upright Digital Breast Tomosynthesis-Guided Vacuum-Assisted Core Biopsy. Acad Radiol. 2020 02; 27(2):204-209. PMID: 31076332.
      Citations: 1     Fields:    Translation:Humans
    30. Baez-Vallecillo L, Raghavendra AS, Hess KR, Barcenas CH, Moulder SL, Tripathy D, Valero V, Murthy RK. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019 Jul; 176(1):227-234. PMID: 30977027.
      Citations: 6     Fields:    Translation:Humans
    31. Hess KR. Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAFV600-Mutant Stage III Melanoma Seems to be Short-Lived. J Clin Oncol. 2019 05 20; 37(15):1354-1355. PMID: 30939097; PMCID: PMC6524987.
      Citations: 1     Fields:    Translation:Humans
    32. George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348. PMID: 30869638; PMCID: PMC6437608.
      Citations: 5     Fields:    Translation:Humans
    33. Viswanathan A, Vedantam A, Hess KR, Ochoa J, Dougherty PM, Reddy AS, Koyyalagunta D, Reddy S, Bruera E. Minimally Invasive Cordotomy for Refractory Cancer Pain: A Randomized Controlled Trial. Oncologist. 2019 07; 24(7):e590-e596. PMID: 30796153; PMCID: PMC6656471.
      Citations: 3     Fields:    Translation:Humans
    34. Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351. PMID: 30610588.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    35. Beechar VB, Prabhu SS, Bastos D, Weinberg JS, Stafford RJ, Fuentes D, Hess KR, Rao G. Correction to: Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy. J Neurooncol. 2019 Jan; 141(2):475. PMID: 30635762.
      Citations:    Fields:    
    36. Janku F, Hess KR, Yap TA. Moving Precision Oncology Forward Amid Myths and Misconceptions. JAMA Oncol. 2018 12 01; 4(12):1788-1789. PMID: 30419079.
      Citations:    Fields:    Translation:Humans
    37. Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433. PMID: 30359477; PMCID: PMC7180384.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    38. Subbiah V, Sen S, Hess KR, Janku F, Hong DS, Khatua S, Karp DD, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam F. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precis Oncol. 2018; 2. PMID: 32913986; PMCID: PMC7446411.
      Citations: 4     Fields:    
    39. Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 12 15; 24(24):6594-6610. PMID: 30181387; PMCID: PMC6317865.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    40. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309. PMID: 30139837; PMCID: PMC6291334.
      Citations: 20     Fields:    Translation:Humans
    41. McQuade JL, Daniel CR, Hess KR, Davies MA. Sex as a predictor of response to cancer immunotherapy. Lancet Oncol. 2018 08; 19(8):e376. PMID: 30102226.
      Citations: 4     Fields:    Translation:Humans
    42. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288. PMID: 30077429.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    43. Speer ME, Huang ML, Dogan BE, Adrada BE, Candelaria RP, Hess KR, Hansakul P, Yang WT, Rauch GM. High risk breast lesions identified on MRI-guided vacuum-assisted?needle?biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol. 2018 Oct; 91(1090):20180300. PMID: 29947265; PMCID: PMC6350470.
      Citations: 6     Fields:    Translation:Humans
    44. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291. PMID: 29668571; PMCID: PMC6028046.
      Citations: 3     Fields:    Translation:Humans
    45. Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE. Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precis Oncol. 2018; 2018. PMID: 31058252; PMCID: PMC6498859.
      Citations: 10     Fields:    
    46. Lacourt TE, Vichaya EG, Escalante C, Manzullo EF, Gunn B, Hess KR, Heijnen CJ, Dantzer R. An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology. 2018 10; 96:109-117. PMID: 29929087; PMCID: PMC6131045.
      Citations: 6     Fields:    Translation:Humans
    47. Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C, Forget MA, Tavera RJ. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428. PMID: 29848573; PMCID: PMC6139043.
      Citations: 43     Fields:    Translation:HumansCells
    48. Speer ME, Adrada BE, Arribas EM, Hess KR, Middleton LP, Whitman GJ. Imaging of Intracystic Papillary Carcinoma. Curr Probl Diagn Radiol. 2019 Jul - Aug; 48(4):348-352. PMID: 30072190.
      Citations: 3     Fields:    Translation:Humans
    49. Gupta V, Coburn N, Kidane B, Hess KR, Compton C, Ringash J, Darling G, Mahar AL. Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review. J Thorac Cardiovasc Surg. 2018 08; 156(2):847-856. PMID: 30011772.
      Citations: 14     Fields:    Translation:Humans
    50. Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncol. 2018 Apr 12; 4(4):e175092. PMID: 29372234; PMCID: PMC5885272.
      Citations: 3     Fields:    Translation:Humans
    51. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305. PMID: 29579338.
      Citations: 6     Fields:    Translation:Humans
    52. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322. PMID: 29449192; PMCID: PMC5840029.
      Citations: 203     Fields:    Translation:Humans
    53. Levin VA, Ictech SE, Hess KR. Clinical importance of eflornithine (a-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol. 2018 04; 7(2):CNS16. PMID: 29378419; PMCID: PMC5977277.
      Citations: 13     Fields:    Translation:HumansAnimals
    54. Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87. PMID: 29161986; PMCID: PMC6425981.
      Citations: 37     Fields:    Translation:Humans
    55. Beechar VB, Prabhu SS, Bastos D, Weinberg JS, Stafford RJ, Fuentes D, Hess KR, Rao G. Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy. J Neurooncol. 2018 Mar; 137(1):57-65. PMID: 29204838; PMCID: PMC5823725.
      Citations: 12     Fields:    Translation:Humans
    56. Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646. PMID: 29159766; PMCID: PMC5962379.
      Citations: 58     Fields:    Translation:Humans
    57. Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607. PMID: 29075985; PMCID: PMC5924418.
      Citations: 40     Fields:    Translation:Humans
    58. Hossain MB, Shifat R, Li J, Luo X, Hess KR, Rivera-Molina Y, Puerta Martinez F, Jiang H, Lang FF, Hung MC, Fueyo J, Gomez-Manzano C. TIE2 Associates with Caveolae and Regulates Caveolin-1 To Promote Their Nuclear Translocation. Mol Cell Biol. 2017 Nov 01; 37(21). PMID: 28760776; PMCID: PMC5640814.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    59. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Me. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov; 67(6):472-492. PMID: 29028110; PMCID: PMC5978683.
      Citations: 454     Fields:    Translation:Humans
    60. Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP. A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. Oncotarget. 2017 Oct 27; 8(52):90488-90495. PMID: 29163847; PMCID: PMC5685768.
      Citations: 7     Fields:    
    61. Sen S, Meric-Bernstam F, Hong DS, Hess KR, Subbiah V. Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. J Natl Cancer Inst. 2017 10 01; 109(10). PMID: 29117359; PMCID: PMC6059192.
      Citations: 7     Fields:    Translation:Humans
    62. An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol. 2017 10; 125(1):80-88. PMID: 28916225.
      Citations: 21     Fields:    Translation:Humans
    63. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017. PMID: 29082359; PMCID: PMC5659750.
      Citations: 62     Fields:    
    64. Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, Kaseb AO, Cohen L, Bruera E. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw. 2017 09; 15(9):1111-1120. PMID: 28874596.
      Citations: 19     Fields:    Translation:HumansAnimals
    65. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173. PMID: 29152071; PMCID: PMC5675623.
      Citations:    Fields:    
    66. Jensen GL, Tang C, Hess KR, Liao Z, Gomez DR. Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer. Clin Exp Metastasis. 2017 06; 34(5):315-322. PMID: 28744603.
      Citations: 3     Fields:    Translation:Humans
    67. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162. PMID: 28729355; PMCID: PMC5902668.
      Citations: 1     Fields:    
    68. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589. PMID: 28730293.
      Citations: 2     Fields:    Translation:Humans
    69. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048. PMID: 28687375; PMCID: PMC5560102.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    70. Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017 06 01; 19(6):786-795. PMID: 28340142; PMCID: PMC5464432.
      Citations: 48     Fields:    Translation:HumansCells
    71. Shahar T, Rozovski U, Hess KR, Hossain A, Gumin J, Gao F, Fuller GN, Goodman L, Sulman EP, Lang FF. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncol. 2017 05 01; 19(5):660-668. PMID: 28453745; PMCID: PMC5464439.
      Citations: 26     Fields:    Translation:HumansCells
    72. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537. PMID: 28411072; PMCID: PMC5597336.
      Citations: 20     Fields:    Translation:Humans
    73. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. PMID: 27893038.
      Citations: 64     Fields:    Translation:HumansCellsCTClinical Trials
    74. Silva-Figueroa AM, Hess KR, Williams MD, Clarke CN, Christakis I, Graham PH, Grubbs EG, Lee JE, Busaidy NL, Perrier ND. Prognostic Scoring System to Risk Stratify Parathyroid Carcinoma. J Am Coll Surg. 2017 Mar 15. PMID: 28427885.
      Citations: 8     Fields:    
    75. Le-Petross HT, Hess KR, Knudtson JD, Lane DL, Moseley TW, Geiser WR, Whitman GJ. Effect of Mammography on Marker Clip Migration After Stereotactic-Guided Core Needle Breast Biopsy. Curr Probl Diagn Radiol. 2017 Nov - Dec; 46(6):410-414. PMID: 28390794.
      Citations:    Fields:    Translation:Humans
    76. Huang ML, Speer M, Dogan BE, Rauch GM, Candelaria RP, Adrada BE, Hess KR, Yang WT. Imaging-Concordant Benign MRI-Guided Vacuum-Assisted Breast Biopsy May Not Warrant MRI Follow-Up. AJR Am J Roentgenol. 2017 Apr; 208(4):916-922. PMID: 28140609.
      Citations: 2     Fields:    Translation:Humans
    77. Vedantam A, Hou P, Chi TL, Dougherty PM, Hess KR, Viswanathan A. Use of Spinal Cord Diffusion Tensor Imaging to Quantify Neural Ablation and Evaluate Outcome after Percutaneous Cordotomy for Intractable Cancer Pain. Stereotact Funct Neurosurg. 2017; 95(1):34-39. PMID: 28088799; PMCID: PMC5455141.
      Citations: 1     Fields:    Translation:Humans
    78. Jensen G, Tang C, Hess KR, Bishop AJ, Pan HY, Li J, Yang JN, Tannir NM, Amini B, Tatsui C, Rhines L, Brown PD, Ghia AJ. Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery. J Radiosurg SBRT. 2017; 5(1):25-34. PMID: 29296460; PMCID: PMC5675505.
      Citations: 5     
    79. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289. PMID: 27861143; PMCID: PMC5349913.
      Citations: 14     Fields:    Translation:Humans
    80. Sneige N, Hess KR, Multani AS, Gong Y, Ibrahim NK. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer. 2017 04 01; 123(7):1115-1123. PMID: 27893937; PMCID: PMC5372352.
      Citations: 11     Fields:    Translation:HumansCells
    81. Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clin Cancer Res. 2017 Mar 15; 23(6):1407-1413. PMID: 27852698; PMCID: PMC5872813.
      Citations: 4     Fields:    Translation:Humans
    82. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE, Forget MA. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168. PMID: 27776519; PMCID: PMC5078889.
      Citations: 64     Fields:    Translation:HumansCells
    83. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448. PMID: 27748430; PMCID: PMC5066200.
      Citations: 7     Fields:    Translation:Humans
    84. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215. PMID: 27599876.
      Citations: 4     Fields:    Translation:Humans
    85. Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430. PMID: 27486883; PMCID: PMC5325454.
      Citations: 11     Fields:    Translation:Humans
    86. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396. PMID: 27649551; PMCID: PMC5355002.
      Citations: 137     Fields:    Translation:HumansCellsCTClinical Trials
    87. Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016 Sep 01; 22(17):4291-301. PMID: 27407096; PMCID: PMC5047439.
      Citations: 37     Fields:    Translation:Humans
    88. Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71. PMID: 27286994.
      Citations: 3     Fields:    Translation:Humans
    89. Raj SD, Amer AM, Garg N, Krishnamurthy S, Hess KR, Park YM, Moseley T, Whitman GJ. Incidental Suspicious Regional Lymph Nodes on Breast Sonography: Is Sampling Necessary? Curr Probl Diagn Radiol. 2017 Mar - Apr; 46(2):100-104. PMID: 27338308.
      Citations:    Fields:    Translation:Humans
    90. Mahar AL, Compton C, Halabi S, Hess KR, Gershenwald JE, Scolyer RA, Groome PA. Critical Assessment of Clinical Prognostic Tools in Melanoma. Ann Surg Oncol. 2016 09; 23(9):2753-61. PMID: 27052645.
      Citations: 15     Fields:    Translation:Humans
    91. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43. PMID: 27018785; PMCID: PMC5071733.
      Citations: 17     Fields:    Translation:HumansCells
    92. Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, B?gler O. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med. 2016 Feb 09; 14:46. PMID: 26861698; PMCID: PMC4746796.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    93. Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52. PMID: 26834058; PMCID: PMC5070554.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    94. Kattan MW, Hess KR, Amin MB, Lu Y, Moons KG, Gershenwald JE, Gimotty PA, Guinney JH, Halabi S, Lazar AJ, Mahar AL, Patel T, Sargent DJ, Weiser MR, Compton C, members of the AJCC Precision Medicine Core. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin. 2016 09; 66(5):370-4. PMID: 26784705; PMCID: PMC4955656.
      Citations: 90     Fields:    Translation:Humans
    95. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62. PMID: 26164085; PMCID: PMC4695071.
      Citations: 4     Fields:    Translation:Humans
    96. Asare EA, Liu L, Hess KR, Gordon EJ, Paruch JL, Palis B, Dahlke AR, McCabe R, Cohen ME, Winchester DP, Bilimoria KY. Development of a model to predict breast cancer survival using data from the National Cancer Data Base. Surgery. 2016 Feb; 159(2):495-502. PMID: 26365950.
      Citations: 3     Fields:    Translation:Humans
    97. Qi Y, Liu X, Liu CG, Wang B, Hess KR, Symmans WF, Shi W, Pusztai L. Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. PLoS One. 2015; 10(7):e0119230. PMID: 26136146; PMCID: PMC4489803.
      Citations: 8     Fields:    Translation:Humans
    98. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41. PMID: 26054632; PMCID: PMC4492245.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    99. Shaitelman SF, Tereffe W, Dogan BE, Hess KR, Caudle AS, Valero V, Stauder MC, Krishnamurthy S, Candelaria RP, Strom EA, Woodward WA, Hunt KK, Buchholz TA, Whitman GJ. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10. PMID: 26279028.
      Citations: 1     Fields:    Translation:Humans
    100. Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703. PMID: 25956795; PMCID: PMC4800487.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    101. Melguizo-Gavilanes I, Bruner JM, Guha-Thakurta N, Hess KR, Puduvalli VK. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol. 2015 May; 123(1):141-50. PMID: 25894594; PMCID: PMC4780341.
      Citations: 25     Fields:    Translation:Humans
    102. Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015 May; 20(5):466-73. PMID: 25802405; PMCID: PMC4425375.
      Citations: 32     Fields:    Translation:Humans
    103. Pan HY, Morani A, Wang WL, Hess KR, Paulino AC, Ludwig JA, Lin PP, Daw NC, Mahajan A. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):349-57. PMID: 25772182; PMCID: PMC4431926.
      Citations: 9     Fields:    Translation:Humans
    104. Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54. PMID: 25680763.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    105. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018. PMID: 25669829; PMCID: PMC6279067.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    106. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46. PMID: 25313136; PMCID: PMC4253408.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    107. Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials Collaborative. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73. PMID: 25239666; PMCID: PMC4288521.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    108. Jardim DL, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS, de Melo Gagliato D. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26. PMID: 25087088; PMCID: PMC5144738.
      Citations: 10     Fields:    Translation:Humans
    109. Abbruzzese JL, Hess KR. New option for the initial management of metastatic pancreatic cancer? J Clin Oncol. 2014 Aug 10; 32(23):2405-7. PMID: 24982449; PMCID: PMC4121501.
      Citations: 6     Fields:    Translation:Humans
    110. Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, Mills GB, Garraway LA, Margolin AA, Getz G, Liang H. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014 Jul; 32(7):644-52. PMID: 24952901; PMCID: PMC4102885.
      Citations: 124     Fields:    Translation:Humans
    111. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9. PMID: 25003695; PMCID: PMC4116527.
      Citations: 7     Fields:    Translation:Humans
    112. Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22. PMID: 24764123.
      Citations: 1     Fields:    Translation:Humans
    113. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8. PMID: 24677057.
      Citations: 20     Fields:    Translation:Humans
    114. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8. PMID: 24668327; PMCID: PMC3983812.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    115. Anderson MD, Hamza MA, Hess KR, Puduvalli VK. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol. 2014 Jun; 16(6):823-8. PMID: 24596117; PMCID: PMC4022226.
      Citations: 14     Fields:    Translation:Humans
    116. Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Barnett CM, Hortob?gyi GN. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist. 2014 Mar; 19(3):228-34. PMID: 24536030; PMCID: PMC3958456.
      Citations: 8     Fields:    Translation:Humans
    117. Hess KR, Levin VA. Getting more out of survival data by using the hazard function. Clin Cancer Res. 2014 Mar 15; 20(6):1404-9. PMID: 24501392.
      Citations: 10     Fields:    Translation:Humans
    118. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203. PMID: 24586081.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    119. Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol. 2014 Jan; 25(1):276-82. PMID: 24356639; PMCID: PMC3895955.
      Citations: 3     Fields:    Translation:Humans
    120. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, McCutcheon IE, Cahill DP. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014 Jan; 16(1):81-91. PMID: 24305719; PMCID: PMC3870823.
      Citations: 161     Fields:    Translation:Humans
    121. Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res. 2014 Jan 15; 20(2):281-8. PMID: 24190980.
      Citations: 18     Fields:    Translation:Humans
    122. Wang-Johanning F, Li M, Esteva FJ, Hess KR, Yin B, Rycaj K, Plummer JB, Garza JG, Ambs S, Johanning GL. Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer. Int J Cancer. 2014 Feb 01; 134(3):587-95. PMID: 23873154; PMCID: PMC4191919.
      Citations: 48     Fields:    Translation:HumansCells
    123. Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):591-9. PMID: 23460246.
      Citations: 22     Fields:    Translation:Humans
    124. Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol. 2013 Apr; 71(4):955-63. PMID: 23377373; PMCID: PMC3977741.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    125. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65. PMID: 23391555; PMCID: PMC3702215.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    126. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6. PMID: 23242617; PMCID: PMC3867793.
      Citations: 9     Fields:    Translation:Humans
    127. Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):449-55. PMID: 23225147; PMCID: PMC3544467.
      Citations: 20     Fields:    Translation:Humans
    128. Hightower E, Cabanillas ME, Fuller GN, McCutcheon IE, Hess KR, Shah K, Waguespack SG, Corley LJ, Devin JK. Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary. 2012 Dec; 15(4):556-61. PMID: 22120760; PMCID: PMC3852837.
      Citations: 5     Fields:    Translation:HumansCells
    129. Lang FF, Sawaya R, Suki D, McCutcheon IE, Hess KR. Glioblastoma resection. J Neurosurg. 2012 May; 116(5):1166-7; author reply 1167-8. PMID: 22385007.
      Citations: 1     Fields:    Translation:Humans
    130. Soto-Salgado M, Bayona M, Hess K, Ortiz AP, Su?rez E, Gonz?lez L, P?rez CM. Report of the 2011 University of Puerto Rico-MD Anderson Cancer Center conference entitled "Population-Based Studies in Hispanics: Methodological Issues in Cancer Research". P R Health Sci J. 2012 Mar; 31(1):39-41. PMID: 22432409.
      Citations:    Fields:    Translation:Humans
    131. Hess KR, Wei C, Qi Y, Iwamoto T, Symmans WF, Pusztai L. Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. BMC Bioinformatics. 2011 Dec 01; 12:463. PMID: 22132775; PMCID: PMC3245512.
      Citations: 5     Fields:    Translation:Humans
    132. Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012 Jul 15; 118(14):3599-606. PMID: 22086614.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    133. Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A, Mathews MS, Ro DI, Alkafeef S, Hsu N, Hamamura M, Yu L, Hess KR, Tromberg BJ, Linskey ME, Zhou YH. EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer. 2011 Sep 28; 10:123. PMID: 21955618; PMCID: PMC3204287.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    134. Liedtke C, Packeisen J, Hess KR, Vogt U, Kiesel L, Kersting C, Korsching E, Brandt B, Buerger H. Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. Eur J Cancer. 2012 Sep; 48(13):2066-74. PMID: 21920731.
      Citations: 4     Fields:    Translation:HumansCells
    135. Dong X, Li Y, Tang H, Chang P, Hess KR, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol. 2012 Apr; 36(2):206-11. PMID: 21852217.
      Citations: 20     Fields:    Translation:Humans
    136. Dong X, Li Y, Chang P, Hess KR, Abbruzzese JL, Li D. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Mol Carcinog. 2012 Jun; 51(6):491-9. PMID: 21681824; PMCID: PMC3179809.
      Citations: 10     Fields:    Translation:HumansCells
    137. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67. PMID: 21699723; PMCID: PMC3218956.
      Citations: 93     Fields:    Translation:HumansCells
    138. Dong X, Li Y, Chang P, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prev Res (Phila). 2011 May; 4(5):758-66. PMID: 21411499; PMCID: PMC3969019.
      Citations: 12     Fields:    Translation:Humans
    139. Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol. 2011 Nov; 22(11):2387-2393. PMID: 21406473.
      Citations: 8     Fields:    Translation:Humans
    140. Hess KR. Statistical design considerations in animal studies published recently in cancer research. Cancer Res. 2011 Jan 15; 71(2):625. PMID: 21239476.
      Citations: 20     Fields:    Translation:Animals
    141. Dong X, Li Y, Hess KR, Abbruzzese JL, Li D. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist. 2011; 16(1):61-70. PMID: 21212431; PMCID: PMC3228057.
      Citations: 26     Fields:    Translation:HumansCells
    142. Zhou YH, Hess KR, Raj VR, Yu L, Liu L, Yung AW, Linskey ME. Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. Biomark Insights. 2010 Dec 22; 5:153-68. PMID: 21234290; PMCID: PMC3018892.
      Citations: 14     
    143. Dong X, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer. 2011 Feb 01; 117(3):480-91. PMID: 20845477; PMCID: PMC3961843.
      Citations: 17     Fields:    Translation:Humans
    144. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010 Nov 01; 16(21):5351-61. PMID: 20829329; PMCID: PMC4181852.
      Citations: 96     Fields:    Translation:Humans
    145. Hess KR. Comparing survival curves using an easy to interpret statistic. Clin Cancer Res. 2010 Oct 15; 16(20):4912-3. PMID: 20732962.
      Citations:    Fields:    Translation:Humans
    146. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD, Thomas RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, Furlanello C, Gallas BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, Chen M, Cheng J, Cheng J, Chou J, Davison TS, Delorenzi M, Deng Y, Devanarayan V, Dix DJ, Dopazo J, Dorff KC, Elloumi F, Fan J, Fan S, Fan X, Fang H, Gonzaludo N, Hess KR, Hong H, Huan J, Irizarry RA, Judson R, Juraeva D, Lababidi S, Lambert CG, Li L, Li Y, Li Z, Lin SM, Liu G, Lobenhofer EK, Luo J, Luo W, McCall MN, Nikolsky Y, Pennello GA, Perkins RG, Philip R, Popovici V, Price ND, Qian F, Scherer A, Shi T, Shi W, Sung J, Thierry-Mieg D, Thierry-Mieg J, Thodima V, Trygg J, Vishnuvajjala L, Wang SJ, Wu J, Wu Y, Xie Q, Yousef WA, Zhang L, Zhang X, Zhong S, Zhou Y, Zhu S, Arasappan D, Bao W, Lucas AB, Berthold F, Brennan RJ, Buness A, Catalano JG, Chang C, Chen R, Cheng Y, Cui J, Czika W, Demichelis F, Deng X, Dosymbekov D, Eils R, Feng Y, Fostel J, Fulmer-Smentek S, Fuscoe JC, Gatto L, Ge W, Goldstein DR, Guo L, Halbert DN, Han J, Harris SC, Hatzis C, Herman D, Huang J, Jensen RV, Jiang R, Johnson CD, Jurman G, Kahlert Y, Khuder SA, Kohl M, Li J, Li M, Li QZ, Li S, Li Z, Liu J, Liu Y, Liu Z, Meng L, Madera M, Martinez-Murillo F, Medina I, Meehan J, Miclaus K, Moffitt RA, Montaner D, Mukherjee P, Mulligan GJ, Neville P, Nikolskaya T, Ning B, Page GP, Parker J, Parry RM, Peng X, Peterson RL, Phan JH, Quanz B, Ren Y, Riccadonna S, Roter AH, Samuelson FW, Schumacher MM, Shambaugh JD, Shi Q, Shippy R, Si S, Smalter A, Sotiriou C, Soukup M, Staedtler F, Steiner G, Stokes TH, Sun Q, Tan PY, Tang R, Tezak Z, Thorn B, Tsyganova M, Turpaz Y, Vega SC, Visintainer R, von Frese J, Wang C, Wang E, Wang J, Wang W, Westermann F, Willey JC, Woods M, Wu S, Xiao N, Xu J, Xu L, Yang L, Zeng X, Zhang J, Zhang L, Zhang M, Zhao C, Puri RK, Scherf U, Tong W, Wolfinger RD, MAQC Consortium, Oberthuer A. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010 Aug; 28(8):827-38. PMID: 20676074; PMCID: PMC3315840.
      Citations: 355     Fields:    Translation:HumansAnimals
    147. Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, Pusztai L. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther. 2010 May; 9(5):1120-7. PMID: 20423993.
      Citations: 10     Fields:    Translation:HumansCells
    148. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2010 Aug; 139(2):464-73, 473.e1-3. PMID: 20416304; PMCID: PMC2910789.
      Citations: 29     Fields:    Translation:HumansCells
    149. Hess KR, Wei C. Learning curves in classification with microarray data. Semin Oncol. 2010 Feb; 37(1):65-8. PMID: 20172367; PMCID: PMC4482113.
      Citations: 3     Fields:    Translation:Humans
    150. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9. PMID: 20107864.
      Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
    151. Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, Shi L, Symmans WF, Pusztai L, Popovici V. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010; 12(1):R5. PMID: 20064235; PMCID: PMC2880423.
      Citations: 98     Fields:    Translation:Humans
    152. Dupart JJ, Trent JC, Lee HY, Hess KR, Godwin AK, Taguchi T, Zhang W. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. Mol Cancer. 2009 Nov 10; 8:99. PMID: 19903356; PMCID: PMC2780392.
      Citations: 8     Fields:    Translation:HumansCells
    153. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov; 10(11):1037-44. PMID: 19801201.
      Citations: 802     Fields:    Translation:HumansPHPublic Health
    154. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WK, Liu TJ. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009 Sep; 94(2):229-34. PMID: 19267183.
      Citations: 31     Fields:    Translation:Humans
    155. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14. PMID: 19241157; PMCID: PMC5921048.
      Citations: 32     Fields:    Translation:HumansCells
    156. Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009 Apr 01; 27(10):1592-9. PMID: 19237629; PMCID: PMC2668967.
      Citations: 31     Fields:    Translation:HumansCells
    157. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008 Oct 15; 113(8):2046-52. PMID: 18756532.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    158. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008 Sep 20; 26(27):4442-8. PMID: 18802157.
      Citations: 74     Fields:    Translation:Humans
    159. Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol. 2008 Dec; 10(6):1010-8. PMID: 18708343; PMCID: PMC2718998.
      Citations: 45     Fields:    Translation:Humans
    160. Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. J Clin Oncol. 2008 Oct 01; 26(28):4679-83. PMID: 18662965.
      Citations: 12     Fields:    Translation:Humans
    161. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008 Oct; 90(1):89-97. PMID: 18581057; PMCID: PMC6059769.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    162. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23. PMID: 18323556.
      Citations: 132     Fields:    Translation:HumansCTClinical Trials
    163. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008 Apr; 10(2):208-15. PMID: 18316473; PMCID: PMC2613823.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    164. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008 Apr; 10(2):216-22. PMID: 18314417; PMCID: PMC2613824.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    165. Liedtke C, Mazouni C, Hess KR, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L, Andr? F. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1275-81. PMID: 18250347.
      Citations: 1030     Fields:    Translation:Humans
    166. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD, North American Brain Tumor Consortium and the National Cancer Institute. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15; 13(24):7401-6. PMID: 18094423; PMCID: PMC4918812.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    167. Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90. PMID: 17896785.
      Citations: 10     Fields:    Translation:Humans
    168. Aoki H, Yokoyama T, Fujiwara K, Tari AM, Sawaya R, Suki D, Hess KR, Aldape KD, Kondo S, Kumar R, Kondo Y. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6603-9. PMID: 18006760.
      Citations: 26     Fields:    Translation:HumansCells
    169. Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res. 2007 Oct 15; 13(20):6080-6. PMID: 17947471.
      Citations: 14     Fields:    Translation:Humans
    170. Jiang R, Choi W, Khan A, Hess K, Gerner EW, Casero RA, Yung WK, Hamilton SR, Zhang W. Activation of polyamine catabolism by N1,N11-diethylnorspermine leads to cell death in glioblastoma. Int J Oncol. 2007 Aug; 31(2):431-40. PMID: 17611701.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    171. Faria SC, Ng CS, Hess KR, Phongkitkarun S, Szejnfeld J, Daliani D, Charnsangavej C. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007 Aug; 189(2):378-85. PMID: 17646464.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    172. Levin VA, Ictech S, Hess KR. Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer. 2007 Jun 22; 7:106. PMID: 17587447; PMCID: PMC1919386.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    173. Aoki H, Iwado E, Eller MS, Kondo Y, Fujiwara K, Li GZ, Hess KR, Siwak DR, Sawaya R, Mills GB, Gilchrest BA, Kondo S. Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J. 2007 Sep; 21(11):2918-30. PMID: 17449721.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    174. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 2007 Mar; 8(3):203-11. PMID: 17329190.
      Citations: 73     Fields:    Translation:Humans
    175. Lecocke M, Hess K. An empirical study of univariate and genetic algorithm-based feature selection in binary classification with microarray data. Cancer Inform. 2007 Feb 23; 2:313-27. PMID: 19458774; PMCID: PMC2675488.
      Citations: 10     
    176. Hess KR. Statistical issues in clinical trial design. Curr Oncol Rep. 2007 Jan; 9(1):55-9. PMID: 17164048.
      Citations:    Fields:    Translation:Humans
    177. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40. PMID: 17200360.
      Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
    178. Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80. PMID: 17075877.
      Citations: 21     Fields:    Translation:Humans
    179. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7. PMID: 17031561.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    180. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006 Sep 01; 24(25):4107-15. PMID: 16908934.
      Citations: 103     Fields:    Translation:HumansCells
    181. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Hortobagyi GN, Pusztai L, G?mez HL. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44. PMID: 16896004.
      Citations: 264     Fields:    Translation:Humans
    182. Armstrong T, Cohen MZ, Hess KR, Manning R, Lee EL, Tamayo G, Baumgartner K, Min SJ, Yung A, Gilbert M. Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J Pain Symptom Manage. 2006 Aug; 32(2):148-54. PMID: 16877182.
      Citations: 16     Fields:    Translation:Humans
    183. Ito H, Aoki H, Kondo Y, Kubicka S, Wirth T, Iwado E, Iwamaru A, Fujiwara K, Hess KR, Lang FF, Sawaya R, Kondo S, K?hnel F. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst. 2006 May 03; 98(9):625-36. PMID: 16670388.
      Citations: 71     Fields:    Translation:HumansAnimalsCells
    184. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol. 2006 Oct; 80(1):83-90. PMID: 16639492.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    185. Wang L, Wei Q, Wang LE, Aldape KD, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol. 2006 Apr 01; 24(10):1627-32. PMID: 16575014.
      Citations: 30     Fields:    Translation:Humans
    186. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer. 2006 Apr 01; 106(7):1624-33. PMID: 16518827.
      Citations: 307     Fields:    Translation:Humans
    187. Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, Wu Y, Gong Y, Hortobagyi GN, Symmans WF, Pusztai L. Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res. 2006 Mar 15; 12(6):1721-7. PMID: 16551855.
      Citations: 8     Fields:    Translation:Humans
    188. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J, North American Brain Tumor Consortium. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93. PMID: 16533878; PMCID: PMC1871932.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    189. Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol. 2006 Apr 10; 24(11):1720-8. PMID: 16520463; PMCID: PMC1435378.
      Citations: 68     Fields:    Translation:HumansCellsCTClinical Trials
    190. Levin VA, Giglio P, Puduvalli VK, Jochec J, Groves MD, Yung WK, Hess K. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol. 2006 May; 78(1):85-90. PMID: 16391896.
      Citations: 24     Fields:    Translation:HumansAnimalsCTClinical Trials
    191. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9. PMID: 16293864.
      Citations: 82     Fields:    Translation:Humans
    192. McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, Aaron J, Tipnis U, Zhang W, Hess K, Aldape K. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005 Oct 01; 104(7):1468-77. PMID: 16088966.
      Citations: 38     Fields:    Translation:HumansCells
    193. Zhou YH, Hess KR, Liu L, Linskey ME, Yung WK. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol. 2005 Oct; 7(4):485-94. PMID: 16212813; PMCID: PMC1871729.
      Citations: 28     Fields:    Translation:Humans
    194. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15; 11(16):5678-85. PMID: 16115903.
      Citations: 602     Fields:    Translation:Humans
    195. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD, North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61. PMID: 16012795.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    196. Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross JS, Hess KR, Tirrell S, Linette G, Hortobagyi GN, Fraser Symmans W, Pusztai L. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn. 2005 Aug; 7(3):357-67. PMID: 16049308; PMCID: PMC1867535.
      Citations: 16     Fields:    Translation:Humans
    197. Sclabas GM, Uwagawa T, Schmidt C, Hess KR, Evans DB, Abbruzzese JL, Chiao PJ. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer. 2005 Jun 15; 103(12):2485-90. PMID: 15861417.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    198. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005 Jun 07; 102(23):8315-20. PMID: 15914550; PMCID: PMC1149405.
      Citations: 129     Fields:    Translation:HumansCells
    199. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103. PMID: 15860869.
      Citations: 32     Fields:    Translation:Humans
    200. Zhou YH, Wu X, Tan F, Shi YX, Glass T, Liu TJ, Wathen K, Hess KR, Gumin J, Lang F, Yung WK. PAX6 suppresses growth of human glioblastoma cells. J Neurooncol. 2005 Feb; 71(3):223-9. PMID: 15735909.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    201. Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, Hess KR, Zhang W, Fidler IJ, Chiao PJ. Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):440-9. PMID: 15701826.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    202. Heimberger AB, Wang E, McGary EC, Hess KR, Henry VK, Shono T, Cohen Z, Gumin J, Sawaya R, Conrad CA, Lang FF. Mechanisms of action of rapamycin in gliomas. Neuro Oncol. 2005 Jan; 7(1):1-11. PMID: 15701277; PMCID: PMC1871627.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    203. Pusztai L, Hess KR. Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol. 2004 Dec; 15(12):1731-7. PMID: 15550577.
      Citations: 21     Fields:    Translation:Humans
    204. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004 Nov 15; 101(10):2293-9. PMID: 15476282.
      Citations: 106     Fields:    Translation:Humans
    205. Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs. 2004 Nov; 22(4):459-66. PMID: 15292716.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    206. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M, North American Brain Tumor Consortium. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9. PMID: 15514370; PMCID: PMC3820102.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    207. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD, North American Brain Tumor Consortium And The National Cancer Institute. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35. PMID: 15292713.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    208. See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol. 2004 Jul; 6(3):253-8. PMID: 15279718; PMCID: PMC1871997.
      Citations: 31     Fields:    Translation:Humans
    209. Li Z, Sclabas GM, Peng B, Hess KR, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer. 2004 Jul 01; 101(1):58-65. PMID: 15221989.
      Citations: 27     Fields:    Translation:HumansCells
    210. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004 Jun; 239(6):818-25; discussion 825-7. PMID: 15166961; PMCID: PMC1356290.
      Citations: 570     Fields:    Translation:Humans
    211. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93. PMID: 15136595.
      Citations: 116     Fields:    Translation:Humans
    212. Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K, Schold C. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer. 2004 Apr 15; 100(8):1712-6. PMID: 15073861.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    213. Schold SC, Kokkinakis DM, Chang SM, Berger MS, Hess KR, Schiff D, Robins HI, Mehta MP, Fink KL, Davis RL, Prados MD. O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol. 2004 Jan; 6(1):28-32. PMID: 14769137; PMCID: PMC1871964.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    214. Prados MD, Yung WK, Fine HA, Greenberg HS, Junck L, Chang SM, Nicholas MK, Robins HI, Mehta MP, Fink KL, Jaeckle KA, Kuhn J, Hess KR, Schold SC, North American Brain Tumor Consortium study. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):33-7. PMID: 14769138; PMCID: PMC1871975.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    215. Raza SM, Fuller GN, Rhee CH, Huang S, Hess K, Zhang W, Sawaya R. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):212-21. PMID: 14734472.
      Citations: 28     Fields:    Translation:Humans
    216. Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J, North American Brain Tumor Consortium study. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):44-54. PMID: 14769140; PMCID: PMC1871968.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    217. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003 Sep 15; 9(11):4247-54. PMID: 14519652.
      Citations: 115     Fields:    Translation:AnimalsCells
    218. Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003 Aug 15; 9(9):3369-75. PMID: 12960124.
      Citations: 89     Fields:    Translation:HumansCells
    219. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15. PMID: 12855612.
      Citations: 43     Fields:    Translation:HumansCells
    220. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M, North American Brain Tumor Consortium. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003 Jun 15; 21(12):2305-11. PMID: 12805331.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    221. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71. PMID: 12784330.
      Citations: 48     Fields:    Translation:Humans
    222. Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003 04; 5(2):89-95. PMID: 12672280; PMCID: PMC1920671.
      Citations: 87     Fields:    Translation:Humans
    223. Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res. 2003 Mar; 9(3):981-90. PMID: 12631596.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    224. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003 Mar; 78(1):105-18. PMID: 12611463.
      Citations: 76     Fields:    Translation:Humans
    225. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res. 2003 Mar; 9(3):955-60. PMID: 12631592.
      Citations: 15     Fields:    Translation:HumansCells
    226. Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology. 2003; 65(3):259-66. PMID: 14657600.
      Citations: 19     Fields:    Translation:Humans
    227. Kim S, Dougherty ER, Shmulevich I, Hess KR, Hamilton SR, Trent JM, Fuller GN, Zhang W. Identification of combination gene sets for glioma classification. Mol Cancer Ther. 2002 Nov; 1(13):1229-36. PMID: 12479704.
      Citations: 35     Fields:    Translation:Humans
    228. Evans DB, Hess KR, Pisters PW. ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. Ann Surg. 2002 Nov; 236(5):694; author reply 694-6. PMID: 12409677; PMCID: PMC1422632.
      Citations: 13     Fields:    Translation:Humans
    229. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 2002 Nov-Dec; 8(6):461-8. PMID: 12500855.
      Citations: 27     Fields:    Translation:Humans
    230. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002 Sep 15; 20(18):3792-803. PMID: 12228199.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    231. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002 Sep 15; 20(18):3804-14. PMID: 12228200.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    232. Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, Patel SR, Benjamin RS, Plager C, Papadopoulos NE, Burgess MA, Pollock RE, Feig BW. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002 Sep 01; 95(5):1120-6. PMID: 12209699.
      Citations: 26     Fields:    Translation:Humans
    233. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5. PMID: 12192324; PMCID: PMC1422591.
      Citations: 76     Fields:    Translation:Humans
    234. Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys. 2002 May 01; 53(1):58-66. PMID: 12007942.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    235. Robins HI, Chang SM, Prados MD, Yung WK, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn JG, Cloughesy T, Junck L, Mehta M. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol. 2002 Apr; 4(2):109-14. PMID: 11916502; PMCID: PMC1920656.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    236. Shmulevich I, Hunt K, El-Naggar A, Taylor E, Ramdas L, Hess KR, Pollock R, Zhang W, Labord? P. Tumor specific gene expression profiles in human leiomyosarcoma: an evaluation of intratumor heterogeneity. Cancer. 2002 Apr 01; 94(7):2069-75. PMID: 11932911.
      Citations: 9     Fields:    Translation:Humans
    237. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002 Mar 01; 20(5):1383-8. PMID: 11870183.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    238. Winnerkvist A, Bartoli S, Iliopoulos DC, Hess KR, Miller CC, Safi HJ. Spinal cord protection during aortic cross clamping: retrograde venous spinal cord perfusion, distal aortic perfusion, and cerebrospinal fluid drainage. Scand Cardiovasc J. 2002 Feb; 36(1):6-10. PMID: 12018769.
      Citations: 1     Fields:    Translation:HumansAnimals
    239. Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, Bruner JM, Zhang W. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 2002 Jan; 12(1):108-16. PMID: 11771519; PMCID: PMC8096049.
      Citations: 25     Fields:    Translation:Humans
    240. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12. PMID: 12491078.
      Citations: 22     Fields:    Translation:Humans
    241. Kunschner LJ, Fine H, Hess K, Jaeckle K, Kyritsis AP, Yung WK. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest. 2002; 20(7-8):948-54. PMID: 12449727.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    242. Herrera CA, Xu L, Bucana CD, Silva el VG, Hess KR, Gershenson DM, Fidler IJ. Expression of metastasis-related genes in human epithelial ovarian tumors. Int J Oncol. 2002 Jan; 20(1):5-13. PMID: 11743636.
      Citations: 8     Fields:    Translation:Humans
    243. Hess KR, Zhang W, Baggerly KA, Stivers DN, Coombes KR. Microarrays: handling the deluge of data and extracting reliable information. Trends Biotechnol. 2001 Nov; 19(11):463-8. PMID: 11602311.
      Citations: 27     Fields:    Translation:Humans
    244. Hess KR, Fuller GN, Rhee CH, Zhang W. Statistical pattern analysis of gene expression profiles for glioblastoma tissues and cell lines. Int J Mol Med. 2001 Aug; 8(2):183-8. PMID: 11445872.
      Citations: 2     Fields:    Translation:HumansCells
    245. Hess KR, Abbruzzese JL. Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol. 2001 Aug 01; 19(15):3445-6. PMID: 11481348.
      Citations: 5     Fields:    Translation:Humans
    246. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001 Aug; 95(2):190-8. PMID: 11780887.
      Citations: 1062     Fields:    Translation:Humans
    247. Pisters PW, Hudec WA, Hess KR, Lee JE, Vauthey JN, Lahoti S, Raijman I, Evans DB. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg. 2001 Jul; 234(1):47-55. PMID: 11420482; PMCID: PMC1421947.
      Citations: 93     Fields:    Translation:Humans
    248. Kunschner LJ, Kuttesch J, Hess K, Yung WK. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol. 2001 07; 3(3):167-73. PMID: 11465397; PMCID: PMC1920617.
      Citations: 25     Fields:    Translation:Humans
    249. Munden RF, Hess KR. "Ditzels" on chest CT: survey of members of the Society of Thoracic Radiology. AJR Am J Roentgenol. 2001 Jun; 176(6):1363-9. PMID: 11373192.
      Citations: 7     Fields:    Translation:Humans
    250. Gutman H, Hess KR, Kokotsakis JA, Ross MI, Guinee VF, Balch CM. Surgery for abdominal metastases of cutaneous melanoma. World J Surg. 2001 Jun; 25(6):750-8. PMID: 11376411.
      Citations: 27     Fields:    Translation:Humans
    251. Kozuch P, Hoff PM, Hess K, Adams J, Newman RA, Lee F, Pazdur R. Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer. 2001 Feb 15; 91(4):815-21. PMID: 11241251.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    252. Hill LR, Hess KR, Stephens LC, Price RE, Gray KN. Correlation of kidney weight and volume and selected skeletal parameters to sex in the adult rhesus monkey (Macaca mulatta). J Med Primatol. 2001 Feb; 30(1):56-60. PMID: 11396864.
      Citations: 3     Fields:    Translation:Animals
    253. Baggerly KA, Coombes KR, Hess KR, Stivers DN, Abruzzo LV, Zhang W. Identifying differentially expressed genes in cDNA microarray experiments. J Comput Biol. 2001; 8(6):639-59. PMID: 11747617.
      Citations: 17     Fields:    Translation:HumansCells
    254. Puduvalli VK, Kyritsis AP, Hess KR, Bondy ML, Fuller GN, Kouraklis GP, Levin VA, Bruner JM. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol. 2000 Nov; 17(5):963-9. PMID: 11029499.
      Citations: 12     Fields:    Translation:Humans
    255. Evans DB, Wolff RA, Hess KR. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 2000 Nov; 232(5):727. PMID: 11066157; PMCID: PMC1421239.
      Citations: 1     Fields:    Translation:Humans
    256. Meric F, Milas M, Hunt KK, Hess KR, Pisters PW, Hildebrandt G, Patel SR, Benjamin RS, Plager C, Papadopolous NE, Burgess MA, Pollock RE, Feig BW. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol. 2000 Oct 01; 18(19):3378-83. PMID: 11013278.
      Citations: 16     Fields:    Translation:Humans
    257. Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000 Oct; 6(10):3878-84. PMID: 11051233.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    258. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000 Feb; 18(3):646-50. PMID: 10653880.
      Citations: 105     Fields:    Translation:HumansCTClinical Trials
    259. Hess KR, Serachitopol DM, Brown BW. Hazard function estimators: a simulation study. Stat Med. 1999 Nov 30; 18(22):3075-88. PMID: 10544307.
      Citations: 26     Fields:    Translation:Humans
    260. Pentz RD, Young LN, Amos CI, Hess KR, Wei Q, Anderlik MR. Informed consent for tissue research. JAMA. 1999 Nov 03; 282(17):1625. PMID: 10553787.
      Citations:    Fields:    
    261. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999 Nov; 5(11):3403-10. PMID: 10589751.
      Citations: 53     Fields:    Translation:Humans
    262. Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK. Response and progression in recurrent malignant glioma. Neuro Oncol. 1999 10; 1(4):282-8. PMID: 11550320; PMCID: PMC1920759.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    263. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, Zhang W. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res. 1999 Sep 01; 59(17):4228-32. PMID: 10485462.
      Citations: 65     Fields:    Translation:Humans
    264. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999 Aug; 17(8):2572-8. PMID: 10561324.
      Citations: 406     Fields:    Translation:Humans
    265. Groves MD, Maor MH, Meyers C, Kyritsis AP, Jaeckle KA, Yung WK, Sawaya RE, Hess K, Bruner JM, Peterson P, Levin VA. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1999 Aug 01; 45(1):127-35. PMID: 10477016.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    266. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB. Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg. 1999 May-Jun; 3(3):263-77. PMID: 10481119.
      Citations: 16     Fields:    Translation:HumansCells
    267. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol. 1999 May; 42(3):227-31. PMID: 10433106.
      Citations: 50     Fields:    Translation:Humans
    268. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999 Apr 15; 59(8):1820-4. PMID: 10213484.
      Citations: 83     Fields:    Translation:Humans
    269. Hill LR, Hess KR, Stephens LC, Tinkey PT, Price RE. Comparison of kidney weight and volume to selected anatomical parameters in the adult female rhesus monkey (Macaca mulatta). J Med Primatol. 1999 Apr; 28(2):67-72. PMID: 10431696.
      Citations: 2     Fields:    Translation:Animals
    270. Sigurdson AJ, Bondy ML, Hess KR, Toms SA, Kyritsis AP, Gu J, Wang LE, Wang X, Adatto P, Bruner JL, Yung WK, Levin VA, Wei Q. Gamma-ray mutagen sensitivity and survival in patients with glioma. Clin Cancer Res. 1998 Dec; 4(12):3031-5. PMID: 9865917.
      Citations: 3     Fields:    Translation:HumansCells
    271. Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X, Chan W, Pershouse MA, Yung WK, Steck PA. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res. 1998 Oct; 4(10):2447-54. PMID: 9796977.
      Citations: 18     Fields:    Translation:Humans
    272. Ritter AM, Hess KR, McLendon RE, Langford LA. Ependymomas: MIB-1 proliferation index and survival. J Neurooncol. 1998 Oct; 40(1):51-7. PMID: 9874186.
      Citations: 14     Fields:    Translation:Humans
    273. Hoque A, Sigurdson AJ, Burau KD, Humphrey HE, Hess KR, Sweeney AM. Cancer among a Michigan cohort exposed to polybrominated biphenyls in 1973. Epidemiology. 1998 Jul; 9(4):373-8. PMID: 9647899.
      Citations: 25     Fields:    Translation:HumansPHPublic Health
    274. Svensson LG, Hess KR, D'Agostino RS, Entrup MH, Hreib K, Kimmel WA, Nadolny E, Shahian DM. Reduction of neurologic injury after high-risk thoracoabdominal aortic operation. Ann Thorac Surg. 1998 Jul; 66(1):132-8. PMID: 9692452.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    275. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol. 1998 Jun; 16(6):2105-12. PMID: 9626210.
      Citations: 20     Fields:    Translation:Humans
    276. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, Wildrick DM. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998 May; 42(5):1044-55; discussion 1055-6. PMID: 9588549.
      Citations: 194     Fields:    Translation:Humans
    277. Hess KR, Wong ET, Yung WK. Assessing response to chemotherapy in malignant glioma: the role of steroids. Neurology. 1998 Apr; 50(4):1197; disscussion 1197-8. PMID: 9566439.
      Citations:    Fields:    Translation:Humans
    278. Wong ET, Jackson EF, Hess KR, Schomer DF, Hazle JD, Kyritsis AP, Jaeckle KA, Yung WK, Levin VA, Leeds NE. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology. 1998 Mar; 50(3):777-81. PMID: 9521274.
      Citations: 18     Fields:    Translation:Humans
    279. Ali-Osman F, Brunner JM, Kutluk TM, Hess K. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2253-61. PMID: 9815622.
      Citations: 26     Fields:    Translation:HumansCells
    280. Spitz FR, Giacco GG, Hess K, Larry L, Rich TA, Janjan N, Cleary KR, Skibber JM. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res. 1997 Oct; 3(10):1685-90. PMID: 9815551.
      Citations: 24     Fields:    Translation:Humans
    281. Levin B, Hess K, Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997 May 12; 157(9):970-6. PMID: 9140267.
      Citations: 18     Fields:    Translation:HumansPHPublic Health
    282. Meterissian SH, Skibber JM, Giacco GG, el-Naggar AK, Hess KR, Rich TA. Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival. Surgery. 1997 May; 121(5):479-87. PMID: 9142144.
      Citations: 2     Fields:    Translation:Humans
    283. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Abbruzzese JL, Ordo?ez NG. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol. 1997 May; 15(5):2056-66. PMID: 9164218.
      Citations: 11     Fields:    Translation:Humans
    284. Strom SS, Hess KR, Sigurdson AJ, Spitz MR, Liang JC. Evaluation of sister chromatid exchange and chromosome breaks in a cohort of untreated Hodgkin's disease patients. Cancer Epidemiol Biomarkers Prev. 1997 Apr; 6(4):291-3. PMID: 9107435.
      Citations: 1     Fields:    Translation:Humans
    285. Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S, Jaeckle KA, Levin VA. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 1997 Mar; 15(3):1063-70. PMID: 9060546.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    286. Bindal RK, Bindal AK, Hess KR. Survival after radiosurgery for brain metastasis: regarding Buatti et al. IJROBP 32(4):1161-1166; 1995. Int J Radiat Oncol Biol Phys. 1996 Sep 01; 36(2):523. PMID: 8892480.
      Citations: 1     Fields:    Translation:Humans
    287. Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res. 1996 Sep; 2(9):1489-97. PMID: 9816325.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    288. Bindal AK, Bindal RK, Hess KR, Shiu A, Hassenbusch SJ, Shi WM, Sawaya R. Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg. 1996 May; 84(5):748-54. PMID: 8622147.
      Citations: 72     Fields:    Translation:Humans
    289. Abbruzzese JL, Abbruzzese MC, Lenzi R, Raber MN, Hess KR. Are time or intensity factors important to the definition of metastases of unknown origin? J Natl Cancer Inst. 1996 Apr 03; 88(7):462-3. PMID: 8618241.
      Citations:    Fields:    Translation:Humans
    290. Kyritsis AP, Bondy ML, Hess KR, Cunningham JE, Zhu D, Amos CJ, Yung WK, Levin VA, Bruner JM. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res. 1995 Dec; 1(12):1617-22. PMID: 9815964.
      Citations: 15     Fields:    Translation:Humans
    291. Bindal RK, Sawaya R, Leavens ME, Hess KR, Taylor SH. Reoperation for recurrent metastatic brain tumors. J Neurosurg. 1995 Oct; 83(4):600-4. PMID: 7674007.
      Citations: 43     Fields:    Translation:Humans
    292. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995 Aug 15; 14(15):1707-23. PMID: 7481205.
      Citations: 196     Fields:    Translation:Humans
    293. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995 Aug; 13(8):2094-103. PMID: 7636553.
      Citations: 76     Fields:    Translation:Humans
    294. Younis GA, Sawaya R, DeMonte F, Hess KR, Albrecht S, Bruner JM. Aggressive meningeal tumors: review of a series. J Neurosurg. 1995 Jan; 82(1):17-27. PMID: 7815129.
      Citations: 18     Fields:    Translation:Humans
    295. Svensson LG, Hess KR, Coselli JS, Safi HJ. Influence of segmental arteries, extent, and atriofemoral bypass on postoperative paraplegia after thoracoabdominal aortic operations. J Vasc Surg. 1994 Aug; 20(2):255-62. PMID: 8040949.
      Citations: 17     Fields:    Translation:Humans
    296. Guinee VF, Olsson H, Hess KR, Taylor SH, Fahey T, Gladikov JV, van den Blink JW, Bonichon F, Dische S, M?ller T, et al. Effect of pregnancy on prognosis for young women with breast cancer. Lancet. 1994 Jun 25; 343(8913):1587-9. PMID: 7911917.
      Citations: 36     Fields:    Translation:Humans
    297. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994 Jun; 12(6):1272-80. PMID: 8201389.
      Citations: 70     Fields:    Translation:Humans
    298. Hess KR. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med. 1994 May 30; 13(10):1045-62. PMID: 8073200.
      Citations: 67     Fields:    Translation:Humans
    299. Kasperlik-Zaluska AA, Migdalska B, Makowska A. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1994 Mar 01; 73(5):1533-5. PMID: 8111724.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    300. Barnes G, Romero L, Hess KR, Curley SA. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol. 1994 Jan; 1(1):73-8. PMID: 7834432.
      Citations: 36     Fields:    Translation:Humans
    301. Guinee VF, Hess KR. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer. 1993 Oct 01; 72(7):2291-2. PMID: 8104093.
      Citations:    Fields:    Translation:Humans
    302. Weg N. Abdominal aortic aneurysm measurement: a critique of methods for comparison studies. Invest Radiol. 1993 Aug; 28(8):787-8. PMID: 8376014.
      Citations:    Fields:    Translation:Humans
    303. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1993 May 15; 71(10):3119-23. PMID: 8490842.
      Citations: 21     Fields:    Translation:Humans
    304. Hess KR. Confidence intervals and survival estimates. J Thorac Cardiovasc Surg. 1991 Sep; 102(3):456-9. PMID: 1881186.
      Citations:    Fields:    Translation:Humans
    305. Staudacher RA, Hess KR, Harris SL, Abu-Khalil J, Heibig J. Percutaneous transluminal coronary angioplasty utilizing prolonged balloon inflations: initial results and six-month follow-up. Cathet Cardiovasc Diagn. 1991 Aug; 23(4):239-44. PMID: 1889077.
      Citations:    Fields:    Translation:Humans
    306. Crawford ES, Hess KR. Abdominal aortic aneurysm. N Engl J Med. 1989 Oct 12; 321(15):1040-2. PMID: 2674718.
      Citations: 2     Fields:    Translation:Humans
    307. Ostojic MC, Young JB, Hess KR. Prediction of left ventricular ejection fraction using a unique method of chest x-ray and ECG analysis: a noninvasive index of cardiac performance based on the concept of heart volume and mass interrelationship. Am Heart J. 1989 Mar; 117(3):590-8. PMID: 2919538.
      Citations: 1     Fields:    Translation:Humans
    308. Griffin JC, Schuenemeyer TD, Hess KR, Glaeser D, Anderson BJ, Romans E, Jenkins MA, Nielsen AP. Pacemaker follow-up: its role in the detection and correction of pacemaker system malfunction. Pacing Clin Electrophysiol. 1986 May; 9(3):387-91. PMID: 2423980.
      Citations: 1     Fields:    Translation:Humans
    309. Crawford ES, Crawford JL, Safi HJ, Coselli JS, Hess KR, Brooks B, Norton HJ, Glaeser DH. Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. J Vasc Surg. 1986 Mar; 3(3):389-404. PMID: 3951025.
      Citations: 100     Fields:    Translation:Humans
    310. Bayesian optimal interval design. Clinical Cancer Research. 22:4291-4301.
    311. Letter to the editor [9] (multiple letters). Annals of Surgery. 232:727.
    312. Reproducibility of variant calls in replicate next generation sequencing experiments. PLoS One. 10.
    313. A diagnostic model for impending death in cancer patients. Cancer.
    314. International Journal of Cancer. 140:208-215.
    315. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults. Oncoscience. 1:522-530.
    316. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. British Journal of Cancer. 113:1003-1009.
    317. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Women's Oncology Review. 4:211-212.
    318. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports. 6.
    319. Coronary Artery Spasm Induced by Stent Implantation. Journal of Interventional Cardiology. 6:149-155.
    320. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 7:86280-86289.
    321. Phase i study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocrine-Related Cancer. 22:431-441.
    322. Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer. Acta Oncologica. 1-7.
    323. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials. Investigational New Drugs. 1-9.
    324. Critical Assessment of Clinical Prognostic Tools in Melanoma. Annals of Surgical Oncology. 1-9.
    325. Oncologist. 21:1149-1155.
    326. Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis. Oncoscience. 1:205-215.
    327. Intratumoral heterogeneity. Cancer.
    328. Dissection of the aorta and dissecting aortic aneurysms. Circulation. 82.
    329. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemotherapy and Pharmacology. 78:167-171.
    330. MET nucleotide variations and amplification in advanced ovarian cancer. Oncoscience. 1:5-13.
    331. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer Journal for Clinicians.
    332. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. Journal of Translational Medicine.
    333. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine. 14.
    334. The association of epidural analgesia and forceps delivery. Regional Anesthesia. 15:76-77.
    335. Extensions and applications of event charts. American Statistician. 54:63-70.
    336. A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. PLoS Computational Biology. 12.
    337. P53 alterations show significant correlation with gene amplification and high S-phase index in breast cancer. International Journal of Oncology. 6:955-962.
    338. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer. Cancer.
    339. Is epidural analgesia the only variable associated with forceps delivery?. Regional Anesthesia. 15:75-76.
    340. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma. Oncotarget. 6:28453-28462.
    341. Chiari and duraplasty. Journal of Neurosurgery. 116:1166-1167.
    342. Phase i study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7:1-11.
    343. Effect of pregnancy on prognosis for young women with breast cancer. Obstetrical and Gynecological Survey. 50:6-7.
    344. Studentizing microarray data. 49-59.
    345. Statistical methods. 13-17.
    346. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 1:540-549.
    347. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 164:550-563.
    348. Characterization of pseudoprogression in patients with glioblastoma. Journal of Neuro-Oncology. 123:141-150.
    349. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 7:64421-64430.
    350. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Obstetrical and Gynecological Survey. 67:164-165.
    351. The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatmentwith themammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab. Oncologist. 20:737-741.
    352. Incidental Suspicious Regional Lymph Nodes on Breast Sonography. Current Problems in Diagnostic Radiology.
    353. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Archives of Dermatological Research. 1-9.
    354. Breast cancer with brainmetastases. Oncologist. 20:466-473.
    355. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.
    356. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology (Switzerland).
    357. Comparison of the accuracy of US-guided biopsy of breast masses performed with 14-gauge, 16-gauge and 18-gauge automated cutting needle biopsy devices, and review of the literature. European Radiology. 1-6.
    358. Re. Investigative Radiology. 28:787-788.
    359. Whole-brain irradiation for patients with brain metastases. The Lancet Oncology. 11:223.
    HESS's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (896)
    Explore
    _
    Co-Authors (323)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _